A kit that includes an absorbent product adapted for mucosal membrane hemostasis, and instructions using the absorbent product is disclosed. The absorbent product can include a liquid permeable pouch, and at least one sheet of absorbent material within the liquid permeable pouch. The instructions can include rolling and/or folding the absorbent product, placing the rolled and/or folded absorbent product proximate the site of the bleeding, and applying pressure to the absorbent product. The instructions can also include inserting the absorbent product into a mucous membrane, such as a nostril or the vaginal canal. Methods of utilizing the absorbent product and the kit are also disclosed.

The present invention is directed to a hemostatic textile, comprising: a material comprising a combination of glass fibers and one or more secondary fibers selected from the group consisting of silk fibers; ceramic fibers; raw or regenerated bamboo fibers; cotton fibers; rayon fibers; linen fibers; ramie fibers; jute fibers; sisal fibers; flax fibers; soybean fibers; corn fibers; hemp fibers; lyocel fibers; wool; lactide and/or glycolide polymers; lactide/glycolide copolymers; silicate fibers; polyamide fibers; feldspar fibers; zeolite fibers, zeolite-containing fibers, acetate fibers; and combinations thereof; the hemostatic textile capable of activating hemostatic systems in the body when applied to a wound. Additional cofactors such as thrombin and hemostatic agents such as RL platelets, RL blood cells; fibrin, fibrinogen, and combinations thereof may also be incorporated into the textile. The invention is also directed to methods of producing the textile, and methods of using the textile to stop bleeding.

The present invention relates generally to agents and devices for promoting hemostasis and, more particularly, to bioresorbable hemostatic pads or patches releasably supported on non-resorbable scaffolds for ease of delivery in the field. A sealant and/or hemostat delivery device comprises a resorbable hemostatic pad having a wound facing side and an opposite back side, with a hemostatic and/or wound sealing agent disposed on the wound facing side; a non-resorbable scaffold having an attachment zone on said scaffold; wherein said hemostatic pad is releasably attached with the back side to the attachment zone. The bond between the scaffold and the resorbable hemostatic pad or wound dressing is either (i) severed prior to removal of the scaffold or (ii) is weakened due to the adhesive bonding them together being moisture-deactivated, or (iii) is released by mechanical disentanglement.

Disclosed are solid dressings for treating wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings.

The present invention provides a hemostatic composite sponge comprising oxidized cellulose and an essentially gelatin-free bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.

Embodiments herein provide hemostatic compositions comprising a plurality of liquid-expandable articles arranged on a backing material. In general, embodiments include methods for treating hemorrhagic injuries. More specifically, there is provided a method to effect rapid hemostatic response and control hemorrhage by introducing a hemostatic composition into a bleeding wound cavity. An embodiment also provides a method of preparing or manufacturing such a hemostatic composition.

The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.

A unique multi-functional emergency bandage stops bleeding by: (1) optimizing mechanical properties and preventing ischemia and/or necrosis while applying enough pressure to help stop bleeding, and (2) incorporating inorganic anti-bleeding nano-structures (embedded within a gauze and/or microbial cellulose) with almost infinite life-time. Additionally, pathogen passage through the bandage is prohibited (via an intermediate filter layer). Together with the overall anti-microbial character of the bandage, the unique multi-functional bandage offers all these vital features within a single design. The unique bandage can be applied by using a single hand and bandaging direction can be changed using a unique binding apparatus. Visual aids, such as printed rectangles, on the final fabric provides the user with an indication of how to control the amount of stretch, as vertical rectangles would turn into horizontal rectangles when stretched too much, whereas rectangles turn to squares around the optimum region of the stress-strain curve.

The present invention relates to a haemostatic material comprising a carrier layer and a material for wound contact comprising at least one haemostat in particulate, granular, powder, flake or short fibrous form. Such a haemostatic material is useful, for example, in reducing or stopping bleeding of a physiological target site in a person or animal, and can also be used to stem bleeding during medical procedures.

A knit hemostatic bandage provided herein can include a continuous rayon fiber and a continuous glass fiber. The knit hemostatic bandage can have a gauge of between 10 and 30 stitches per inch. The knit hemostatic bandage can have a Young's modulus of elasticity of less than 50 MPa.